InnoCare Pharma Limited (09969.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

19.8x

Market Cap

HKD 27.08B

MomentumView details →

1D Return

+4.06%

YTD Return

+24.96%

RSI (14)

60.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

19.8x

Market Cap

HKD 27.08B

RSI (14)

60.4

MomentumView details →

1D Return

+4.06%

YTD Return

+24.96%

ProfitabilityView details →

Gross Margin

89.85%

Net Margin

32.94%

EBITDA Margin

31.32%

ROE (TTM)

11.83%

ROA (TTM)

8.09%

Asset Turnover

0.26x

GrowthView details →

Revenue YoY

+108.49%

EPS YoY

+479.61%

FCF YoY

+222.38%

Revenue CAGR 3Y

+54.30%

EPS CAGR 3Y

+238.46%

EBITDA YoY

+410.37%

EarningsView details →

EPS (Actual)

HKD 0.09

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

HKD 0.00

Avg Surprise (4Q)

—

Rev Surprise

−12.82%

Capital & dividendView details →

Debt/Equity

0.29x

Current Ratio

4.21x

Quick Ratio

4.12x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

2.75B

Net Income (TTM)

907.26M

Op. CF (TTM)

320.62M

Next earningsNov 16, 2026 →

Latest newsMore news →

InnoCare Pharma announced its first-half 2026 results, reporting a net profit of 246 million yuan, turning from a loss in the same period last year.11d ago

InnoCare announced that its combination of orelabrutinib and mesutoclax was granted breakthrough therapy designation by the Center for Drug Evaluation of the National Medical Products Administration for the treatment of patients with marginal zone lymphoma who have received at least one prior therapy.32d ago

Similar companies

Insmed IncorporatedINSM BioNTech SEBNTX Incyte CorporationINCY Royalty Pharma plcRPRX Roivant Sciences Ltd.ROIV Simcere Pharmaceutical Group Limited02096.HK Find similar companies →

Latest newsMore news →

InnoCare Pharma announced its first-half 2026 results, reporting a net profit of 246 million yuan, turning from a loss in the same period last year.11d ago InnoCare announced that its combination of orelabrutinib and mesutoclax was granted breakthrough therapy designation by the Center for Drug Evaluation of the National Medical Products Administration for the treatment of patients with marginal zone lymphoma who have received at least one prior therapy.32d ago Directors Jisong Cui, Renbin Zhao, and Xiangyang Chen of InnoCare Pharma reduced their holdings of the company's A shares through centralized bidding.46d ago